RỐI LOẠN LIPID MÁU VÀ NGUY CƠ MẮC BỆNH ĐỘNG MẠCH VÀNH Ở BỆNH NHÂN SUY THẬN MẠN GIAI ĐOẠN CUỐI LỌC MÁU CHU KỲ TẠI BỆNH VIỆN THẬN HÀ NỘI THEO THANG ĐIỂM FRAMINGHAM

Abstract

Dyslipidemia is a well-established risk factor for cardiovascular events, particularly notable in individuals with end-stage renal disease (ESRD) undergoing hemodialysis. Objectives: Describe the characteristics of dyslipidemia and evaluate the risk of coronary artery disease (CAD) in hemodialysis patients based on the Framingham Risk Score. Methods: A cross-sectional descriptive study was conducted at Hanoi Nephrology Hospital in 2023, involving 353 hemodialysis patients. Lipid profiles were assessed, and Framingham Risk Scores were calculated to determine CAD risk categories. Results and conclusion: The prevalence of dyslipidemia, defined as the presence of at least one abnormal lipid component, was 80,5%. Specifically, decreased high-density lipoprotein cholesterol (HDL-C) was observed in 73,4% of patients, while elevated triglycerides were noted in 52,6%. The Framingham Risk Score categorization revealed a distribution of very high risk (15,6%), high risk (5,3%), intermediate risk (8,8%), and low risk (70,3%). Age and high systolic blood pressure were identified as significant contributors to the increased risk of CAD.